Canopy Growth (NASDAQ:CGC) & Lyra Therapeutics (OTCMKTS:LYRA) Head to Head Contrast

Lyra Therapeutics (OTCMKTS:LYRA) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Risk & Volatility

Lyra Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 0.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Lyra Therapeutics and Canopy Growth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1	0	0	0	1.00
Canopy Growth	1	2	2	0	2.20

Profitability

This table compares Lyra Therapeutics and Canopy Growth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-7,266.08%	N/A	-59.82%
Canopy Growth	-65.33%	-21.91%	-14.34%

Valuation and Earnings

This table compares Lyra Therapeutics and Canopy Growth”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$400,000.00	0.89	-$28.92 million	($19.15)	-0.01
Canopy Growth	$251.01 million	1.66	-$190.29 million	($0.45)	-2.06

Lyra Therapeutics has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Canopy Growth beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

About Canopy Growth

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.